Delivery Order SPE2DR25D2104-SPE2DR26F3QTK
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $12,247.59 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 10 mg/0.5 ml pens on December 12, 2025, with final completion scheduled for December 15, 2025. This firm fixed price delivery order was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The order represents a routine pharmaceutical procurement supporting federal healthcare...
- The Defense Logistics Agency awarded a delivery order valued at $4,483.14 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pens on a firm fixed-price basis. The contract, which was competitively awarded without set-aside designation, was executed on December 10, 2025, with an ultimate completion date of December 11, 2025. Performance will be fulfilled from the vendor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $6,165.74 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pens on November 20, 2025, with completion scheduled for November 21, 2025. This delivery order is issued under a firm fixed-price contract structure without any set-aside designation, indicating competitive procurement. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a $13,067.60 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pens under a firm fixed price contract. The order is scheduled for completion by August 8, 2025, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation and represents a relatively small-value transaction...
- The Defense Logistics Agency awarded a $16,297.57 delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pens. The contract represents a firm fixed-price delivery order with an ultimate completion date of August 14, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's demonstrated...
- The Defense Logistics Agency awarded a $19,343.26 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pens. This competitively awarded, firm fixed-price contract is classified as a non-set-aside procurement and requires completion by July 25, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $2,214.84 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 10 mg/0.5 mL pen injections on November 20, 2025, with completion scheduled for November 21, 2025. This firm fixed-price delivery order, issued without a set-aside designation, represents a competitively awarded transaction under AmerisourceBergen's existing contract vehicle with DLA. The product will be delivered to the company's corporate headquarters location...
- The Defense Logistics Agency awarded a $17,804.99 delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pens on December 12, 2025, with an ultimate completion date of December 15, 2025. This non-set-aside, firm fixed-price delivery order represents a competitive award under the company's broader pharmaceutical supply relationship with the federal government. The award was placed to AmerisourceBergen's Corporate Office location in Conshohocken,...
- The Defense Logistics Agency awarded a $1,476.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 5 mg/0.5 mL pens on December 3, 2025, with completion expected by December 4, 2025. This delivery order was issued without a set-aside designation and represents a competitive procurement from AmerisourceBergen's existing indefinite delivery contract (IDC) with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's facility in...
- The Defense Logistics Agency awarded a delivery order valued at $15,446.43 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pens on November 26, 2025, with an ultimate completion date of November 28, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement...
- SPE2DR25D2104Indefinite Delivery Contract
- SPE2DR25D2104-SPE2DR26F3QTKDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $10,017.00 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 10 mg/0.5 mL pens on December 5, 2025, with an ultimate completion date of December 8, 2025. This firm fixed-price delivery order was competitively awarded without a set-aside designation. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and serves as a primary pharmaceutical distributor for federal medical supply chains. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This comprehensive prime vendor agreement enables AmerisourceBergen to supply a broad range of pharmaceuticals and medical supplies to support military and veteran healthcare systems globally. The company's federal procurement portfolio demonstrates significant capability in delivering specialty medications across multiple therapeutic domains, positioning it as a critical vendor for Defense Health Agency and other federal healthcare customers through the DLA's global pharmaceutical support programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.0k | 12/4/25 |